Verastem Oncology (NASDAQ:VSTM) Stock In Focus After Q4 Earnings Update

March 16, 2023

Biopharmaceutical firm Verastem Oncology (NASDAQ:VSTM) is focused on the advancements of new medicines for cancer patients and yesterday, it was in focus after it announced its financial results for the full fiscal year and the three month period ended on December 31, 2022. It could be a good idea for investors to take a look at some of the highlights from the financial results. Trading Data On Wednesday, VSTM stock…


Verastem Inc (NASDAQ:VSTM) Stock Rallies As RBC Capital Initiates Coverage

April 18, 2022

Last Thursday the Verastem Inc (NASDAQ:VSTM) stock had been in the middle of a major rally and had managed to end the day with gains of as much as 15% amidst heavy interest. Trading Data On Thursday, VSTM stock soared 15.70% to $1.77 with 30.07 million shares, compared to its average volume of 2.31 million shares. The stock moved within a range of $1.5700 – 2.1299 after opening trade at…